Go Pro
NASDAQ:LMAT

LeMaitre Vascular (LMAT) Stock Price, News & Analysis

LeMaitre Vascular logo
$102.19 -1.38 (-1.33%)
Closing price 04:00 PM Eastern
Extended Trading
$102.20 +0.00 (+0.00%)
As of 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About LeMaitre Vascular Stock (NASDAQ:LMAT)

Advanced

Key Stats

Today's Range
$100.68
$102.70
50-Day Range
$88.61
$105.70
52-Week Range
$79.00
$118.01
Volume
186,260 shs
Average Volume
272,836 shs
Market Capitalization
$2.34 billion
P/E Ratio
37.71
Dividend Yield
0.98%
Price Target
$112.60
Consensus Rating
Moderate Buy

Company Overview

LeMaitre Vascular, Inc. is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D. LeMaitre, a vascular surgeon who sought to improve patient outcomes through innovation, the company has introduced numerous technologies that have become standards in surgical practice. Early success with devices such as the LeMaitre valvulotome laid the groundwork for ongoing expansion into complementary product categories. Over the decades, the company has grown both organically and through targeted acquisitions, continuously enhancing its ability to deliver comprehensive solutions for blood flow restoration.

LeMaitre Vascular sells its products worldwide, with direct sales and distribution partnerships spanning North America, Europe, Asia-Pacific and Latin America. Its international footprint allows it to collaborate with hospitals, surgical centers and healthcare systems around the globe, adapting its technology portfolio to meet regional regulatory requirements and clinical preferences. By maintaining a network of field-based clinical specialists and customer support teams, the company ensures that its innovations are effectively integrated into surgical workflows.

Committed to ongoing research and development, LeMaitre Vascular invests in advancing technologies that address unmet clinical needs in vascular surgery. The company’s leadership team brings together expertise in medical device engineering, regulatory affairs and commercial strategy, guiding efforts to expand into new markets and therapeutic areas. Through its focus on quality, innovation and customer partnership, LeMaitre Vascular aims to improve long-term patient outcomes in the treatment of peripheral vascular disease.

AI Generated. May Contain Errors.

LeMaitre Vascular Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
77th Percentile Overall Score

LMAT MarketRank™: 

LeMaitre Vascular scored higher than 77% of companies evaluated by MarketBeat, and ranked 127th out of 832 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    LeMaitre Vascular has received a consensus rating of Moderate Buy. The company's average rating score is 2.56, and is based on no strong buy ratings, 5 buy ratings, 4 hold ratings, and no sell ratings.

  • Upside Potential

    LeMaitre Vascular has a consensus price target of $112.60, representing about 10.2% upside from its current price of $102.19.

  • Amount of Analyst Coverage

    LeMaitre Vascular has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about LeMaitre Vascular's stock forecast and price target.
  • Earnings Growth

    Earnings for LeMaitre Vascular are expected to grow by 9.00% in the coming year, from $3.00 to $3.27 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of LeMaitre Vascular is 37.71, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 39.99.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of LeMaitre Vascular is 37.71, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 27.62.

  • Price to Earnings Growth Ratio

    LeMaitre Vascular has a PEG Ratio of 2.84. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    LeMaitre Vascular has a P/B Ratio of 5.89. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about LeMaitre Vascular's valuation and earnings.
  • Percentage of Shares Shorted

    6.99% of the float of LeMaitre Vascular has been sold short.
  • Short Interest Ratio / Days to Cover

    LeMaitre Vascular has a short interest ratio ("days to cover") of 4.5.
  • Change versus previous month

    Short interest in LeMaitre Vascular has recently increased by 9.00%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    LeMaitre Vascular has a dividend yield of 0.98%, which is in the bottom 25% of all stocks that pay dividends.

  • Dividend Growth

    LeMaitre Vascular has been increasing its dividend for 14 years.

  • Dividend Coverage

    The dividend payout ratio of LeMaitre Vascular is 36.90%. This payout ratio is at a healthy, sustainable level, below 75%.

  • Dividend Sustainability

    Based on earnings estimates, LeMaitre Vascular will have a dividend payout ratio of 30.58% next year. This indicates that LeMaitre Vascular will be able to sustain or increase its dividend.

  • Read more about LeMaitre Vascular's dividend.
  • News Sentiment

    LeMaitre Vascular has a news sentiment score of 1.16. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.89 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 4 news articles for LeMaitre Vascular this week, compared to 3 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, LeMaitre Vascular insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $5,906,174.00 in company stock.

  • Percentage Held by Insiders

    7.40% of the stock of LeMaitre Vascular is held by insiders.

  • Percentage Held by Institutions

    84.64% of the stock of LeMaitre Vascular is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about LeMaitre Vascular's insider trading history.
Receive LMAT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for LeMaitre Vascular and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

LMAT Stock News Headlines

LMAT LeMaitre Vascular, Inc.
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Trump has issued emergency support to accelerate the rollout, and it's already live in multiple states. The Financial Times reports Sam Altman is personally calling people to build this for OpenAI. A few little-known companies control the entire supply chain - meaning anyone who wants access must go through them. Their stocks are available to buy right now.tc pixel
Lemaitre Vascular (LMAT) Receives a Buy from Sidoti
See More Headlines

LMAT Stock Analysis - Frequently Asked Questions

LeMaitre Vascular's stock was trading at $81.10 at the beginning of 2026. Since then, LMAT stock has increased by 26.0% and is now trading at $102.19.

LeMaitre Vascular, Inc. (NASDAQ:LMAT) announced its quarterly earnings results on Tuesday, May, 5th. The medical instruments supplier reported $0.68 earnings per share for the quarter, beating analysts' consensus estimates of $0.66 by $0.02. The company's revenue for the quarter was up 11.1% on a year-over-year basis.
Read the conference call transcript
.

The following companies are subsidiaries of LeMaitre Vascular: Artegraft, CardioCel, Tru-Incise (Eze-Sit) US, VascuCel, LeMaitre Cardial SAS, Syntel and Python, ProCol, and more.

LeMaitre Vascular's top institutional shareholders include Annex Advisory Services LLC (1.09%), Hennion & Walsh Asset Management Inc. (0.06%), Handelsbanken Fonder AB (0.04%) and Contravisory Investment Management Inc. (0.01%). Insiders that own company stock include George W Lemaitre, David B Roberts, Joseph P Pellegrino Jr, Lawrence J Jasinski, Bridget A Ross, Trent G Kamke and John A Roush.
View institutional ownership trends
.

Shares of LMAT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that LeMaitre Vascular investors own include Humana (HUM), American Water Works (AWK), Waste Connections (WCN), Voyager Therapeutics (VYGR), The RMR Group (RMR), DiamondRock Hospitality (DRH) and AUO (AUOTY).

Company Calendar

Last Earnings
5/05/2026
Record date for 6/4 Dividend
5/21/2026
Ex-Dividend for 6/4 Dividend
5/21/2026
Dividend Payable
6/04/2026
Today
7/30/2026
Next Earnings (Estimated)
8/04/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED PRODUCTS
Sub-Industry
Medical Equipment
Current Symbol
NASDAQ:LMAT
CIK
1158895
Employees
490
Year Founded
1983

Price Target and Rating

High Price Target
$127.00
Low Price Target
$95.00
Potential Upside/Downside
+10.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.56
Research Coverage
9 Analysts

Profitability

EPS (Trailing Twelve Months)
$2.71
Trailing P/E Ratio
37.71
Forward P/E Ratio
34.06
P/E Growth
2.88
Net Income
$57.73 million
Net Margins
24.35%
Pretax Margin
31.46%
Return on Equity
15.36%
Return on Assets
9.78%

Debt

Debt-to-Equity Ratio
0.42
Current Ratio
14.32
Quick Ratio
12.20

Sales & Book Value

Annual Sales
$249.60 million
Price / Sales
9.36
Cash Flow
$2.86 per share
Price / Cash Flow
35.69
Book Value
$17.35 per share
Price / Book
5.89

Miscellaneous

Outstanding Shares
22,850,000
Free Float
21,160,000
Market Cap
$2.34 billion
Optionable
Optionable
Beta
0.52

Social Links

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

This page (NASDAQ:LMAT) was last updated on 7/30/2026 by MarketBeat.com Staff.
From Our Partners